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Cytotoxic lymphocyteskill bacteria-infectedcells, but themechanismsatwork remainunclear.Walch
et al. show that these lymphocytes deliver a toxic molecular trio in a two-step process, penetrating
first the infected cells and then delivering bactericidal granzymes into the intracytoplasmic bacteria.Killer lymphocytes such as natural killer
(NK) cells and CD8+ T cells contribute to
the elimination of viruses and intracellular
bacteria by inducing the death of infected
cells. This killing involves the release of
lytic granules containing cytotoxic mole-
cules, including perforin and granzymes
in all mammals, and granulysin in humans
and some other mammals but not in mice.
Perforin binds to cell membranes where it
generates pores that allow the delivery of
lytic granule content into the target cell
cytosol (Figure 1) (Pipkin and Lieberman,
2007). Granzymes are proteases with a
broad substrate spectrum; they are not
known to play a direct role in the elimina-
tion of intracellular pathogens. Granulysin
is a saposin-like lipid-binding protein and
is toxic for bacteria, parasites, fungi, and
tumors (Clayberger and Krensky, 2003;
Stenger et al., 1998). At physiological
levels, granulysin is not sufficient for per-
meabilizing target cell membranes, but
with the help of perforin, it can be internal-
ized and is thought to exert its bactericidal
activity by generating osmotic shock. In
this issue of Cell, Walch et al. (2014) bring
a new and comprehensive view of the
bactericidal roles of granulysin and gran-
zymes.
They first show that the combination of
granulysin and granzyme at sublytic con-
centrations induces bacterial growth
arrest and death and demonstrate the
essential role of granzymes for bacterial
elimination. Confocal imaging reveals that
granulysin decorates the surface walls of
bacteria and allows the entry of gran-
zymes. Importantly, Walch et al. provideseveral lines of evidence to illustrate that
bacterial death does not depend on host
cell apoptosis. First, the combination of
perforin and granzymes induces host cells
apoptosiswithout directly impairing bacte-
rial survival, whereas the addition of granu-
lysin in the assay is absolutely required for
bacterial killing. Second, treatment with a
caspase inhibitor or overexpression of an
antiapoptotic factor protects the host cell
fromgranzyme-induced apoptosis without
affecting bacterial killing. Finally, in the
presenceofCD8+Tcells, bacterial elimina-
tion occurs before the death of infected
cells.
By taking advantage of a transgenic
mouse expressing human granulysin
(Huang et al., 2007), the authors show
that granulysin can increase the efficiency
of L. monocytogenes clearance by 1,000-
fold during a primary challenge in vivo.
Perforin, but not granzyme B, is abso-
lutely required for the granulysin-medi-
ated effect, suggesting compensation by
other granzymes. At 3 days postinfection,
the T cell response remains weak, thereby
indicating that the benefit of granulysin
activity could be attributed to NK cells or
other innate lymphocytes. However, the
exact identity of the cytotolytic cells
involved in the response to primary
L. monocytogenes infection awaits further
investigation. Immune protection against
L. monocytogenes during a secondary
challenge relies on bacteria-specific
memory CD8+ T cells. The observation
that mice expressing transgenic granuly-
sin are more resistant to this secondary
challenge further supports the role ofCell 1granulysin against bacterial infection. It
would be interesting to test whether other
saposin-like molecules contribute to bac-
terial defense in the mouse.
Innate immune phagocytes such as
neutrophils and macrophages can dam-
age bacteria via the generation of radical
oxygen species (ROS). Interestingly, gran-
zymes can also generate ROS and their
scavengers block cytolysis by killer lym-
phocytes (Martinvalet et al., 2005). Walch
et al. thus further assess whether gran-
zymes can induceROSproduction in bac-
teria, once delivered by granulysin into the
microbe. Indeed, by using a fluorescent
reporter, they show that ROS production
inside bacteria depends on granulysin-
delivered granzymes. Moreover, bacteria
overexpressing enzymes involved in
ROS degradation, such as superoxide
dismutase and catalases, are protected
from granzyme-induced damage.
Granzymes A/B generate ROS in mito-
chondria of mammalian cells by cleaving
proteins of the electron transport chain
complex I (ETC I) (Martinvalet et al.,
2008). In the present report, Walsh et al.
show that granzyme B can also cleave
thebacterialETC Icomplex. In theabsence
of ETC I, genetically modified bacteria are
resistant to granzyme-induced ROS but
eventually died from granzymes attack.
Further experiments are necessary to
define the mechanisms by which these
bacteria are killed. Preliminary analysis re-
veals thatgranzymeBcould targetapprox-
imately 100 to 200 molecules in E. coli and
L.monocytogenes. Therefore, even if gran-
zymes may degrade oxidoreductases in57, June 5, 2014 ª2014 Elsevier Inc. 1251
Figure 1. A Two-Step Process for Targeting Intracytoplasmic Bacteria
Step 1. Perforin binds to the cell membrane and generates pores allowing the delivery of lytic granule content into the infected cell. Step 2. Granulysin penetrates
the bacterial membrane to facilitate the entry of granzymes into intracytoplasmic bacteria.While granzymes can limit bacterial spreading by inducing apoptosis of
infected cells, direct delivery of granzymes into bacteria mediated by granulysin eliminates bacteria independently of host cell death.various bacteria, it is important to note that
granzyme-mediated bacterial death is a
complex program of damage that disrupts
keypathways involved inbacterial survival.
Thiswide target spectrumofgranzymes in-
dicates thatmultiplemechanismscould be
employed to eliminate diverse bacteria
strains growing under various conditions,
including both aerobic and anaerobic
strains. These results thus illustrate the
strength of these bactericidal mechanisms
for combating bacterial evasion. Notably,
there are other serine proteases and sapo-
sin-likemoleculespresent inmacrophages
and granulocytes, raising the intriguing
question of whether these innate phago-
cytes use comparable mechanisms for
bacterial defense.
NK cells express high levels of granu-
lysin. Although NK cell deficiencies have
not been associated with susceptibility
to bacterial disease (Jouanguy et al.,
2013), findings in this paper (Walch
et al., 2014) prompt investigators to revisit
their role in antibacterial defense. It will
also be interesting to look at granulysin
expression in other innate lymphocytes
such as NKT cells, mucosa-associated
invariant T cells, and innate lymphoid
cell subsets.1252 Cell 157, June 5, 2014 ª2014 Elsevier InPrevious works have reported the
involvement of granulysin in host de-
fense against tuberculosis, leprosy, and
malaria (Clayberger and Krensky, 2003).
Granulysin also participates in the elimi-
nation of C. neoformans, which can
cause fungal meningitis and encephalitis
in AIDS patients (Clayberger and Kren-
sky, 2003). Along this line, granulysin
production has been shown to be defec-
tive in patients with HIV (Zheng et al.,
2007). Recently, genetic polymorphims
in granulysin have been associated
with differential abilities to clear hepatitis
B virus-infected cells (Park et al., 2012).
Future experiments will thus be crucial
to fully appreciate the biological rele-
vance of the perforin/granulysin/gran-
zymes trio in host defense against
bacteria, parasites, fungi, viruses, and
possibly even tumor cells.
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